1. Home
  2. ADNT vs HRMY Comparison

ADNT vs HRMY Comparison

Compare ADNT & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adient plc

ADNT

Adient plc

N/A

Current Price

$19.25

Market Cap

1.5B

ML Signal

N/A

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

N/A

Current Price

$38.79

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ADNT
HRMY
Founded
2016
2017
Country
Ireland
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
2.0B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ADNT
HRMY
Price
$19.25
$38.79
Analyst Decision
Hold
Strong Buy
Analyst Count
10
9
Target Price
$21.90
$51.33
AVG Volume (30 Days)
1.2M
802.8K
Earning Date
01-27-2026
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
50.44
EPS
N/A
3.17
Revenue
$14,535,000,000.00
$825,944,000.00
Revenue This Year
$1.36
$23.11
Revenue Next Year
$2.11
$16.15
P/E Ratio
N/A
$12.26
Revenue Growth
N/A
21.13
52 Week Low
$10.04
$25.52
52 Week High
$26.16
$40.93

Technical Indicators

Market Signals
Indicator
ADNT
HRMY
Relative Strength Index (RSI) 48.60 66.02
Support Level $18.69 $38.12
Resistance Level $19.37 $40.87
Average True Range (ATR) 0.62 1.25
MACD 0.18 -0.07
Stochastic Oscillator 78.41 65.10

Price Performance

Historical Comparison
ADNT
HRMY

About ADNT Adient plc

Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Share on Social Networks: